Benzinga · Sep 11, 2026
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
MN
NASDAQ · MNKD
MannKind Corporation
Healthcare · Biotechnology
$3.56
Up+$0.03 (+0.94%)
Updated Sep 16, 2026, 5:22 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.78B
- P/E ratio
- 53.97
- Dividend yield
- 0.00%
- 52-week range
- $2.23 – $4.55
- Volume
- 3.7M
- Avg. volume
- 3.97M
Price performance
MNKD price history
1M range · 20 trading sessions · Daily adjusted prices
MNKD closed at $3.56 after 20 trading sessions, down 12.53% for the selected period.
- Last close
- $3.56
- Period change
- -12.53%
- Period low
- $3.56
- Period high
- $4.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.74 | $3.75 | $3.535 | $3.56 | 3.7M |
| Sep 14, 2026 | $3.76 | $3.84 | $3.73 | $3.75 | 3.13M |
| Sep 11, 2026 | $3.83 | $3.85 | $3.73 | $3.75 | 2.47M |
| Sep 10, 2026 | $3.90 | $3.90 | $3.76 | $3.79 | 3.21M |
| Sep 9, 2026 | $4.155 | $4.36 | $3.92 | $3.94 | 5.19M |
| Sep 8, 2026 | $4.00 | $4.32 | $4.00 | $4.16 | 4.93M |
| Sep 4, 2026 | $3.92 | $4.095 | $3.92 | $4.06 | 2.81M |
| Sep 3, 2026 | $4.05 | $4.07 | $3.96 | $3.96 | 2.33M |
| Sep 2, 2026 | $3.965 | $4.09 | $3.965 | $4.04 | 2.59M |
| Sep 1, 2026 | $3.97 | $4.025 | $3.95 | $3.98 | 2.23M |
| Aug 31, 2026 | $3.94 | $4.02 | $3.90 | $4.01 | 2.81M |
| Aug 28, 2026 | $4.06 | $4.075 | $3.93 | $3.95 | 1.99M |
| Aug 27, 2026 | $4.05 | $4.12 | $4.04 | $4.06 | 2.07M |
| Aug 26, 2026 | $4.16 | $4.19 | $4.05 | $4.09 | 1.77M |
| Aug 25, 2026 | $4.10 | $4.235 | $4.10 | $4.16 | 3.19M |
| Aug 24, 2026 | $4.13 | $4.14 | $4.06 | $4.07 | 2.81M |
| Aug 21, 2026 | $4.28 | $4.355 | $4.11 | $4.15 | 3.2M |
| Aug 20, 2026 | $4.35 | $4.36 | $4.135 | $4.26 | 3.42M |
| Aug 19, 2026 | $4.10 | $4.40 | $4.10 | $4.395 | 5.44M |
| Aug 18, 2026 | $3.87 | $4.10 | $3.87 | $4.07 | 4.6M |
Latest MNKD news
The latest Smart Investors Daily articles mentioning MNKD.
Stock researchCompany · Overview
MNKD research
Overview
Company profile and research snapshot.
Company profile
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 6, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| May 7, 2026 | Wells Fargo | Overweight | — |
| May 7, 2026 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching
MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.
Benzinga · Sep 9, 2026
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind licenses Technosphere GLP-1 tech to Rose Pharma for weight management development.
Yahoo · Sep 9, 2026
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, pat
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
